Diagnostic assistance, quantification, characterization, image reconstruction: medical artificial intelligence at your fingertips for radiology.
Back to AI solutions

Transpara

AI solution for breast cancer detection and diagnosis

Discover

Transpara assists radiologists in their interpretation of a mammography exam. Transpara provides a probability of the presence of breast cancer based on automatically detected and AI-scored lesions. Transpara detection works on 2D and tomosynthesis.

Breast cancer is the most commonly diagnosed cancer in women, and accounts for 1 in 4 annual cancer cases worldwide. The European guidelines recommend screening in all women aged 45 to 74 years between every 2-3 years. Breast cancer screening is challenging, even to the expert eye, and the balance of not missing any cancers, while not calling too many False Positives is crucial.
Transpara

Automatic density determination

Categorization of the breast density in either category A-B-C-D


Automatic lesion detection: soft tissue lesions and microcalcifications

Segmentation and contouring of suspicious regions.


Evaluation of the level of malignancy of each lesion detected.

Definition of a regional score for each microcalcification and suspicious tissue lesion.


Analysis of the overall probability that cancer is present in a mammogram.

Categorization of the examination based on an overall score.


Automatic comparison of today's exam with up to 3 previous exams


Increase confidence in your diagnosis, both for normal and suspected cases, thanks to the dual reading of the AI

Adds another layer of security with alerts that provide global test scores

Identify and qualify benign or malign lesions faster in suspecious regions

Save time, secure your diagnosis and optimize your workflow with Incepto

Request a demo

Publications

  1. Hupse, R. et al. Computer-aided Detection of Masses at Mammography: Interactive Decision Support versus Prompts. Radiology 266, 123–129 (2013).

  2. Läng et al. Artificial intelligence-supported screen reading versus standard double reading in the Mammography Screening with Artificial Intelligence trial (MASAI): a clinical safety analysis of a randomised, controlled, non-inferiority, single-blinded, screening accuracy study. The Lancet 2023 August

  3. Schaffter, T. et al. Evaluation of Combined Artificial Intelligence and Radiologist Assessment to Interpret Screening Mammograms. JAMA Netw Open 3, e200265 (2020).

  4. Sasaki, M. et al. Artificial intelligence for breast cancer detection in mammography: experience of use of the ScreenPoint Medical Transpara system in 310 Japanese women. Breast Cancer 27, 642–651 (2020).

  5. Lång, K. et al. Identifying normal mammograms in a large screening population using artificial intelligence. Eur Radiol (2020) doi:10.1007/s00330-020-07165-1.

  6. Rodriguez-Ruiz, A. et al. Can we reduce the workload of mammographic screening by automatic identification of normal exams with artificial intelligence? A feasibility study. Eur Radiol 29, 4825–4832 (2019).

  7. Rodriguez-Ruiz, A. et al. Stand-Alone Artificial Intelligence for Breast Cancer Detection in Mammography: Comparison With 101 Radiologists. 7 (2019).

  8. Le, E. P. V., Wang, Y., Huang, Y., Hickman, S. & Gilbert, F. J. Artificial intelligence in breast imaging. Clinical Radiology 74, 357–366 (2019).

  9. Bahl, M. Detecting Breast Cancers with Mammography: Radiology 2 (2019) doi:https://doi.org/10.1148/radiol.2018182404.

  10. Rodríguez-Ruiz, A. et al. Detection of Breast Cancer with Mammography: Effect of an Artificial Intelligence Support System. Radiology 181371 (2018) doi:10.1148/radiol.2018181371.

Regulatory

Transpara medical device is a regulated health product that bears the CE mark, Class IIb. Notified Body: DEKRA Certification B.V. n°0344. Manufacturer: ScreenPoint Medical B.V. Transpara is a diagnostic tool and shall not be used alone to recommend medical care for diagnostic purposes. Please read the instructions in the user manual carefully. Please contact contact@incepto-medical.com for more information. Last update: 2024/11/27

Contact us to know if this product is available in your country.

Publisher

ScreenPoint Medical is a Dutch company founded in 2014 by Professors Nico Karssemeijer and Mike Brady. Pioneers in their field, they assembled a team of experts in breast imaging and artificial intelligence to develop a decision support algorithm. The team’s ultimate goal is to facilitate early detection of breast cancer, improving survival rates and enabling earlier treatment with less invasive methods.